Incyte (INCY) Delnica Cena
Incyte Cena
V zadnjih 19 letih so prihodki Incyte rasli 31,7 % letno in dosegli 5,14 Mrd. USD. Dobiček na delnico je rasel 68,6 % letno v zadnjih 10 letih. Za Incyte je čista marža 25,0 % padla v primerjavi s 31,8 % pred nekaj leti. Konsenzna 12-mesečna ciljna cena za Incyte je 130,00 USD, približno nad tečaj za 11,5 %. Od 35 analitikov jih 18 priporoča nakup — skupni konsenz je Nakup.
Cena delnice Incyte
Do teh podatkov prek Eulerpool API
100.000 zahtevkov/mes. brezplačno · brez kartice
Incyte poslovni model in analiza delnice
Pogosto postavljena vprašanja o delnici Incyte
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analitiki trenutno določajo povprečno ciljno ceno 128,38 USD za delnico Incyte (mediana: 130,00 USD), kar pomeni +10,1 % glede na zadnjo ceno. Konsenz temelji na 35 ocenah.
35 analitikov trenutno ocenjuje delnico Incyte: 18 priporoča nakup, 17 držanje in 0 prodajo. Za 2026 analitiki pričakujejo, da bo Incyte ustvaril prihodke 5,93 Mrd. USD in dobiček na delnico 3,11 USD.
Po trenutnem tečaju se delnica Incyte trguje po 104,64 EUR (116,60 USD).
Delnica Incyte (INCY) je uvrščena na 8 borzah, med njimi: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
pričakovane prihodki za Incyte znašajo 5,93 Mrd. USD. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.
pričakovane dobiček za Incyte znaša 637,41 Mio. USD. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.
Razmerje cena-dobiček (P/E) Incyte je trenutno 37,46. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice Incyte.
Razmerje cena-prihodki (P/S) Incyte je trenutno 4,02. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice Incyte.
Eulerpool ocena kvalitete za Incyte je 6/10.
ISIN Incyte je US45337C1027. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
WKN Incyte je 896133. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.
Ticker Incyte je INCY. Ticker simbol se uporablja za trgovanje z delnicami Incyte na borzi.
Incyte delnica
Incyte Konkurenčna skupina
Incyte Ticker
Incyte FIGI
Vse ključne kazalnike in poglobljeno analizo Incyte v detaljnem pregledu
Naša analiza delnic Incyte vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Incyte. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: